Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing

Frontiers in Oncology

Qiaoling Liu¹  Weihua Yan²  Hua Zhu³  Dantong Sun³  Helei Hou³ 

[1] Department of Medical Oncology, Qingdao West Coast New Area Central Hospital, Qingdao, China;Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China;Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China;

关键词: nimotuzumab;    resistance;    PIK3CA;    mTOR;    PD-L1;    esophageal squamous cell carcinoma;   

DOI  :  10.3389/fonc.2020.574523

来源: DOAJ

【 摘 要 】

Esophageal squamous cell carcinoma (ESCC) is a deadly disease with a low 5-year survival rate. Anti-epidermal growth factor receptor (EGFR) therapy has been widely used in the treatment of malignancies, and chemotherapy regimens that include nimotuzumab have been confirmed to have satisfactory efficacy among esophageal carcinoma (EC) patients. However, a subpopulation of patients may develop resistance to nimotuzumab. Here, we report an advanced ESCC patient who experienced hyperprogressive disease induced by immune checkpoint inhibitors and was then treated with a chemotherapy regimen containing nimotuzumab. NGS examination of this patient demonstrated that PIK3CA mutation and a RICTOR amplification might participate in primary and acquired resistance to nimotuzumab, respectively, via the PI3K/AKT/mTOR signaling pathway.

【 授权许可】

Unknown